Day: September 7, 2022

September 7, 2022

• Leiden University Medical Center joins global network of partners in the development of Philips Spectral Angio CT suite and its use in clinical research, bringing spectral CT imaging technology into an integrated hybrid angio CT suite with the aim of innovating a range of treatment procedures
• CIRSE 2022 presentation by University of Insubria (Varese, Italy) details positive results of study that uses spectral CT to better guide lung tumor biopsies  
• Philips and University of Pennsylvania announce collaboration to investigate spectral CT guidance during interventional oncology procedures and its potential to confirm treatment effectiveness in real time

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced new milestones in the development of the world’s first spectral detector angio CT solution – Philips Spectral Angio CT suite – bringing the company’s breakthrough spectral CT imaging technology into an integrated hybrid angio CT suite. By combining its award-winning [1] Spectral CT 7500 system and its Image Guided Therapy System – Azurion with FlexArm – in a fully integrated interventional suite solution, Philips aims to give physicians immediate access to these two key imaging modalities in a single room, enabling innovation in minimally-invasive procedures in areas such as oncology, stroke, and trauma care.

Philips today announced a new clinical partner and highlighted clinical studies that focus on the added value of using spectral CT imaging technology during interventional procedures.

Expanding Philips’ clinical network
Leiden University Medical Center (Leiden, the Netherlands) has joined Philips’ global network of clinical partners to investigate how its spectral detector angio CT solution could potentially offer new treatment opportunities and improve patient care.

“We are excited to co-create an innovation that could play a defining role in improving patient care in the space of interventional oncology,” said Mark Burgmans, MD, Head of Interventional Radiology at Leiden University Medical Center. “Adding spectral CT imaging to the interventional suite will enable us to offer new treatment opportunities, avoid moving patients from one imaging suite to another, and offer the unique benefits of spectral CT information when you need it.”

Other leading clinical institutes that Philips is working with on this innovation are Mayo Clinic (Rochester, MN, U.S.) and Baptist Health’s Miami Cardiac & Vascular Institute (Miami, FL, U.S.).

Philips Spectral Angio CT suite combines the company’s latest diagnosis and treatment technologies. Philips Image Guided Therapy System – Azurion with FlexArm – is the company’s next-generation image-guided therapy platform, integrating best in class imaging systems, software, and specialized diagnostic and therapeutic devices to support exceptional treatment for the most complex procedures. The addition of Philips’ award-winning Spectral CT 7500 system means physicians only need one scan to capture all the spectral information required to differentiate and quantify different tissues. Spectral CT enables improved detection, delineation, and quantification of lesions, leading to better-informed planning for minimally-invasive procedures and more precise interventions. It has already proved its worth in other areas of oncology – for example, it has demonstrated higher sensitivity in detecting malignant findings and improved readings of incidental findings [2][3]. With its ability to improve tissue characterization, the Spectral CT 7500 offers significant benefits over conventional CT.

Through continuous research, Philips is building clinical evidence that supports the added value of spectral CT imaging for diagnosis and treatment guidance.

Research results show better targeted biopsies using spectral CT guidance
At this year’s Cardiovascular and Interventional Radiological Society of Europe Annual Meeting (CIRSE 2022, September 10-14, Barcelona, Spain) a presentation is being given by Filippo Piacentino, interventional radiologist at the University of Insubria (Varese, Italy), on the value of spectral CT imaging guidance for performing high-confidence tumor biopsies [4]. The results being presented illustrate the potential for Philips’ spectral CT technology to better guide biopsies by distinguishing between active and non-active regions in a tumor. Ensuring that a biopsy contains a high number of actively dividing cancer cells is important for high-confidence diagnosis.

“With conventional CT, large masses may appear as a largely uniform mass, making highly targeted biopsy difficult,” said Filippo Piacentino. “By fusing images from Philips’ XperGuide live needle guidance with images from spectral CT, that are color-coded based on the effective atomic number of tissues and provide a large amount of additional information, we can now investigate the possibility of obtaining better defined biopsy targets with a fewer number of inconclusive biopsies.”

New clinical collaboration on reduction of the risk of tumor recurrence
Philips also today announced a research collaboration with the University of Pennsylvania (Pennsylvania, PA, U.S.) to study the practicality of using spectral CT-based tissue temperature mapping to provide real-time feedback during tumor thermal ablation procedures to confirm its effectiveness before the patient leaves the room. This will potentially reduce the risk of localized tumor recurrence.

“Announcing these important milestones in the development of our unique Philips Spectral Angio CT suite shows our strong commitment and progress in co-creating the future of image-guided therapy,” said Karim Boussebaa, General Manager of Image Guided Therapy Systems at Philips. “By combining the best of our award-winning modalities into a single suite we aim to unlock new treatment approaches that could benefit both patients and their physicians.”

Visit Philips at CIRSE 2022
To learn more about Philips Spectral Angio CT suite, visit Philips at CIRSE 2022 and join the Philips symposia in which leading physicians will share their latest clinical insights on using this new imaging approach in interventional oncology. You can register via our dedicated CIRSE 2022 webpage.

[1] Minnie Award for Best New Radiology Device
[2] Analysis by Aarhus University Hospital Aarhus, Denmark. Results from case studies are not predictive of results in other cases. Results in other cases may vary.
[3] Analysis by University Hospital Cleveland, USA. Results from case studies are not predictive of results in other cases. Results in other cases may vary.
[4] Filippo Piacentino, ‘Spectral CT as innovative imaging guidance in large lesions lung biopsies. XperGuide and Z-effective fusion for more defined targets, more diagnostic samplings and more biomarkers information’. CIRSE 2022

For further information, please contact:

Joost Maltha
Philips Global Press Office
Tel: +31 6 10 55 8116
Email: joost.maltha@philips.com

Fabienne van der Feer
Philips Image Guided Therapy
Tel.: +31 622 698 001
E-mail: fabienne.van.der.feer@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 79,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

• Philips Spectral Angio CT suite

September 6, 2022

These masks may continue to be used according to the updated instructions and labeling if patients or people in close proximity to them do not have implanted metallic medical devices or metallic objects in the body

Pittsburgh, Pennsylvania – Royal Philips’ (NYSE: PHG; AEX: PHIA) subsidiary Philips Respironics is alerting users of certain CPAP or Bi-Level PAP therapy masks with magnetic headgear clips or straps that these devices should not be used by or near patients and their household members, caregivers and bed partners who have metallic implanted devices or metallic objects (such as metallic splinters) in the body. The magnetic headgear clips are used to attach the headgear straps to the masks, which is a method that is commonly used in the sleep therapy devices industry.

This is a voluntary notification to users of specific CPAP or Bi-Level PAP therapy masks containing such magnetic clips to inform them of the updated instructions and labeling. All users should read and follow Philips Respironics’ voluntarily updated warning and added contraindication described below. This represents a new and industry-leading practice.

Contraindication: Use of the mask is contraindicated for patients and their household members, caregivers and bed partners that may be in close vicinity to patients using the masks, that have implanted devices that may be affected by magnets, including but not limited to:

• Pacemakers
• Implantable cardioverter defibrillators (ICD)
• Neurostimulators
• Magnetic metallic implants/electrodes/valves placed in upper limbs, torso, or higher (i.e., neck and head)
• Cerebral spinal fluid (CSF) shunts (e.g., ventriculo peritoneal (VP) shunt)
• Aneurysm clips
• Embolic coils
• Intracranial aneurysm intravascular flow disruption devices
• Metallic cranial plates, screws, burr hole covers, and bone substitute devices
• Metallic splinters in the eye
• Ocular implants (e.g., glaucoma implants, retinal implants)
• Certain contact lenses with metal
• Implants to restore hearing or balance that have an implanted magnet (such as cochlear implants, implanted bone conduction hearing devices, and auditory brainstem implants)
• Magnetic denture attachments
• Metallic gastrointestinal clips
• Metallic stents (e.g., aneurysm, coronary, tracheobronchial, biliary)
• Implantable ports and pumps (e.g., insulin pumps)
• Hypoglossal nerve stimulators
• Devices labeled as MR (Magnetic Resonance) unsafe
• Magnetic metallic implants not labeled for MR or not evaluated for safety in a magnetic field

Patients should stop using the affected mask if the implant/medical device is contraindicated against the mask magnets. Patients should consult their physician immediately to determine if another mask can be used for their therapy. In the interim, switch to a non-magnetic mask if available, for continued therapy. Patients should properly dispose of the mask that has magnets after an alternative is obtained.

These masks may continue to be used according to the updated instructions and labeling if patients or people in close proximity to them do not have implanted metallic medical devices or metallic objects in the body.

Warning: Magnets with a magnetic field strength of 400 mT are used in the mask. With the exception of the devices identified in the contraindication, ensure that the mask is kept at least 6 inches (approx. 15 cm) away from any other medical implants or medical devices that can be impacted by the magnetic fields to avoid possible effects from localized magnetic fields. This includes household members, caregivers, and bed partners that may be in close vicinity to patients that use the masks.

Impacted masks include (see attached image):

• Amara View Full Face Mask
• DreamWisp Nasal Mask
• DreamWear Full Face Mask
• Wisp and Wisp Youth Nasal Mask
• Therapy Mask 3100 NC/SP

More than 17 million masks containing magnetic clips have been distributed by Philips Respironics to date. As of August 30, 2022, Philips Respironics has received 14 reports of patients suggesting that the mask magnets may have impacted their medical devices including pacemaker interference, pacemaker failure leading to replacement, need of shunt adjustment, resetting of automatic implantable cardioverter defibrillator (AICD), seizures, defibrillator shutting off periodically, arrhythmia, irregular blood pressure, change in heartbeats, and cognitive issues.

Patients with questions may contact Philips Respironics’ customer service at 1-800-345-6443, (Monday – Friday; 8:30 AM ET to 8:00 PM ET) for more information about non-magnetic mask options. Patients may also contact their Durable Medical Equipment (DME) provider, which supplied the masks affected by this notice.

Any adverse events experienced with the use of masks containing magnetic clips should be reported to the FDA’s MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, by mail at MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch Web site at www.fda.gov/medwatch.

This voluntary medical device corrective action has been reported to the regulatory agencies in the countries where these masks are available.

Media contact:
Mario Fante
Philips Global Press Office
Tel.: +1 603 560 9226
E-mail: mario.fante@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 79,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

• Overview of impacted masks

Solution provides visibility, intelligence and operational control to optimize rubber tire gantry crane fleet utilization and reduce TEU handling costs

ATLANTA , Sept. 07, 2022 (GLOBE NEWSWIRE) — Navis, a leading global provider of port and terminal operating systems and carrier and vessel technology solutions, today announced Port of Tanjung Pelepas successfully implemented Navis RTG Optimization to improve utilization of its rubber tire gantry crane fleet and reduce handling costs per TEU. RTG Optimization processes multiple dynamic business rules and complex operating constraints to automate execution decisions, increase crane productivity and improve operating efficiency.

As one of the world’s busiest container ports and Malaysia’s largest container terminal with an annual capacity of 12.5 million TEUs, Port of Tanjung Pelepas operates state-of-the-art facilities that include 172 rubber tire gantry cranes to manage container stacking on-site. Port of Tanjung Pelepas is a joint venture between MMC Corporation and APM Terminals, a leading global ports group. PTP is one of the first APMT terminals to implement Navis RTG Optimization.

“We are excited to partner with Port of Tanjung Pelepas and APMT to support their business goals,” said Kirk Knauff, CEO of Navis. “RTG Optimization is an example of the innovation we are driving in our execution platform to unlock new value for our customers.”

As the premier global provider of terminal operating systems, Navis’s deep domain knowledge, implementation agility and ease of partnership enabled successful implementation and delivery of RTG Optimization at Port of Tanjung Pelepas.

Marco Neelsen, Chief Executive Officer of Port of Tanjung Pelepas said, “The transition of digitalization and automation is speeding up in the entire maritime industry. To secure efficient, sustainable operations and business competitiveness, PTP has proactively invested in its assets and infrastructure aligned with the PTP ESG agenda and digital strategy roadmap. PTP is committed to continue with the journey and further create sustainable value for our customers, shareholders and other stakeholders.”

Joe Schofield, Chief Operating Officer of Port of Tanjung Pelepas said, “Digitalization is the way of the future, and our goal is to use technology to create a safer work environment for our workforce while simultaneously improving our efficiency, productivity, and customer experience.

“Our recent accomplishment in becoming the first port in Malaysia to surpass the 1 million TEUs handling mark in a month is a good example of how enhanced visibility across all RTGs in our yard and upcoming jobs at our terminal, enable us to take strategic action to enhance our efficiency, crane productivity and truck turnaround time. This simultaneously provides our workforce with an advanced tool to continue delivering best-in-class service for our customers.”

About Navis, LP
Navis, the premier port and terminal operating system and provider of carrier and vessel technology solutions, combines industry best practices with innovative technology and world-class services to enable customers, regardless of cargo type, to maximize performance and reduce risk. Through a holistic approach to operational optimization, Navis customers benefit from improved visibility, velocity and measurable business results. Whether tracking cargo through a terminal, improving vessel safety and cargo capacity, optimizing rail network planning and asset utilization, automating equipment operations, or managing multiple terminals through an integrated, centralized solution, Navis helps all customers streamline operations.

About the Port of Tanjung Pelepas
The Port of Tanjung Pelepas (PTP) is Malaysia’s largest container terminal. The port delivers reliable, efficient and advanced services to major shipping lines and box operators, providing shippers in Malaysia and abroad extensive connectivity to the global market.

PTP is a joint venture between MMC Corporation Berhad (70%), a leading utilities and infrastructure group and APM Terminals (30%), a leading global ports group with a global port network in 62 countries.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0f7d11e6-8909-4a49-816d-3e2d7ddf1db8

Media Contact:
Suzy Swindle
sswindle@kaleris.com / suzy.swindle@navis.com

Highly layered magnetic material is compatible with semiconductor packaging 

RENO, Nev., Sept. 06, 2022 (GLOBE NEWSWIRE) — Atlas Magnetics, Co., “AM,” is a Nevada-based fabless semiconductor company focused on advance material deposition on standard semiconductor packaging film to create unique IC solutions. AM announces a high-performance magnetic material to reduce the size of the magnetic components used in consumer and IoT electronic circuits effectively removing the inductor from the PCB in applications such as DC/DC power conversion.

AM solves the problem of direct integration of magnetics into integrated circuits “chips” by electroplating highly layered magnetic alloys directly on semiconductor epoxy packaging films for short connection to the semiconductor die using standard IC bumping processes.

This long-desired concept of using available semiconductor manufacturing processes to remove discrete components, such as inductors and transformers, was previously hindered by cost, frequency response, and incompatible processes. However, this development resolves these barriers while delivering the promised size reductions and performance enhancements by magnetic material deposition at temperatures and pressures compatible with semiconductor packaging.

“While layering magnetic materials to create high frequency, high efficiency cores is nothing new, what’s new is how to cost effectively create micron to sub-micron layering. This is accomplished by reducing the process steps per layer from 13 to just 4. This simplified process allows new magnetic materials to be engineered for frequency (60 MHz or greater) and Qs (up to 35) with layering up to 60+ layers,” stated Atlas Magnetics CEO, John McDonald. “When these 0.2 to 0.4 mm cores are used in a finished inductor or transformer, values of up to 1 μH for lower power applications, and for high-power reduced inductance applications current densities of up to 10A/mm2 can be achieved.

In fact, the layering can be so fine as to yield materials with unique mechanical and electrical parameters. This opens new avenues of research for novel materials not previously economically feasible.”

More information: www.atlasmagnetics.com

About Atlas Magnetics, Co.
Atlas Magnetic, Co., a Nevada corporation, was Series A funded in late July 2021 with $22.8M raised. AM has since grown to 40+ employees located around the world with primary research being conducted at the Nevada Center for Applied Research (NCAR) located at the University of Nevada, Reno (UNR).

Atlas Magnetics, Co.
Media Contact: 
May Teeratrakoonchai
may@atlasmagnetics.com
408-502-4093